

# Haitham W Tuffaha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8614128/publications.pdf>

Version: 2024-02-01

61  
papers

1,095  
citations

567281

15  
h-index

434195

31  
g-index

62  
all docs

62  
docs citations

62  
times ranked

1633  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Clinical Pharmacy Services on Patient Management in the Chemotherapy Infusion Clinics: A 5-Year Study at a Comprehensive Cancer Center. <i>Journal of Pharmacy Practice</i> , 2022, 35, 686-690.	1.0	1
2	Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan. <i>PharmacoEconomics - Open</i> , 2022, 6, 137-145.	1.8	2
3	Methodological Approaches to Cost-Effectiveness Analysis in Saudi Arabia: What Can We Learn? A Systematic Review. <i>MDM Policy and Practice</i> , 2022, 7, 238146832210868.	0.9	3
4	Exercise in preventing falls for men with prostate cancer: a modelled cost-utility analysis. <i>Supportive Care in Cancer</i> , 2022, 30, 5037-5046.	2.2	1
5	Value of Information Analysis: Are We There Yet?. <i>PharmacoEconomics - Open</i> , 2021, 5, 139-141.	1.8	5
6	A Theoretically Informed Approach to Support the Implementation of Pre-Operative Anemia and Iron Deficiency Screening, Evaluation, and Management Pathways: Protocol for a Type Two Hybrid-Effectiveness Study. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 1037-1044.	2.7	1
7	A Review of Web-Based Tools for Value-of-Information Analysis. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 645-651.	2.1	4
8	Demonstrating the value of early economic evaluation alongside clinical trials: Exercise medicine for men with metastatic prostate cancer. <i>European Journal of Cancer Care</i> , 2021, 30, e13479.	1.5	5
9	The perceptions of informal carers of older people with dementia about the role of their pharmacists. <i>International Journal of Pharmacy Practice</i> , 2021, 29, 465-470.	0.6	2
10	Cost-effectiveness analysis of home-based rehabilitation compared to usual care for people with inoperable lung cancer. <i>European Journal of Cancer Care</i> , 2021, 30, e13501.	1.5	4
11	Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review. <i>Supportive Care in Cancer</i> , 2020, 28, 2079-2093.	2.2	29
12	The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review. <i>Supportive Care in Cancer</i> , 2020, 28, 5661-5671.	2.2	17
13	PNS23 Setting Health Priorities in Low-Income and Middle-Income Countries in the ASIA-Pacific Region: The Case of Papua New Guinea. <i>Value in Health Regional Issues</i> , 2020, 22, S84-S85.	1.2	0
14	Patient involvement in surgical wound care research: A scoping review. <i>International Wound Journal</i> , 2020, 17, 1462-1482.	2.9	12
15	Cost-Effectiveness Analysis of Supervised Exercise Training in Men with Prostate Cancer Previously Treated with Radiation Therapy and Androgen-Deprivation Therapy. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 727-737.	2.1	15
16	Cost of vascular access devices in public hospitals in Queensland. <i>Australian Health Review</i> , 2019, 43, 511-515.	1.1	31
17	International HTA Experience with Targeted Therapy Approvals for Lung Cancer. <i>PharmacoEconomics - Open</i> , 2019, 3, 103-117.	1.8	4
18	A Framework to Prioritise Health Research Proposals for Funding: Integrating Value for Money. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 761-770.	2.1	12

#	ARTICLE	IF	CITATIONS
19	Adaptations to cognitive problems reported by breast cancer survivors seeking cognitive rehabilitation: A qualitative study. <i>Psycho-Oncology</i> , 2019, 28, 2042-2048.	2.3	5
20	Improving medication adherence in people with dementia through a technological design. <i>Journal of Pharmacy Practice and Research</i> , 2019, 49, 482-485.	0.8	1
21	PCN95 COST-EFFECTIVENESS ANALYSIS OF GERMLINE BRCA MUTATION TESTING AND OLAPARIB TREATMENT IN METASTATIC BREAST CANCER: AN EVALUATION OF CODEPENDENT TECHNOLOGIES. <i>Value in Health</i> , 2019, 22, S454.	0.3	3
22	PCN349 VALUE OF INFORMATION ANALYSIS GUIDING THE REIMBURSEMENT DECISION OF OLAPARIB FOR METASTATIC BREAST CANCER. <i>Value in Health</i> , 2019, 22, S504.	0.3	0
23	New challenges in psycho-oncology: Economic evaluation of psychosocial services in cancer: Challenges and best practice recommendations. <i>Psycho-Oncology</i> , 2019, 28, 3-10.	2.3	9
24	The Australian Managed Entry Scheme: Are We Getting it Right?. <i>Pharmacoeconomics</i> , 2018, 36, 555-565.	3.3	17
25	Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. <i>Genetics in Medicine</i> , 2018, 20, 985-994.	2.4	76
26	Medication Adherence in Older Patients With Dementia: A Systematic Literature Review. <i>Journal of Pharmacy Practice</i> , 2018, 31, 322-334.	1.0	78
27	Rare Cancers, no Rare Solutions: Risk Sharing Arrangemnts to Reimburse Medicines for Rare Cancers in Australia. <i>Value in Health</i> , 2018, 21, S110.	0.3	1
28	Value For Money, the Overlooked Aspect in Research Funding Decisions. <i>Value in Health</i> , 2018, 21, S55.	0.3	0
29	PROGRAM IN DETAIL. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 25-49.	1.1	0
30	Directing research funds to the right research projects: a review of criteria used by research organisations in Australia in prioritising health research projects for funding. <i>BMJ Open</i> , 2018, 8, e026207.	1.9	8
31	Dressings and securements for the prevention of peripheral intravenous catheter failure in adults (SAVE): a pragmatic, randomised controlled, superiority trial. <i>Lancet, The</i> , 2018, 392, 419-430.	13.7	107
32	Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 91.e7-91.e15.	1.6	11
33	A Program to Increase Research Productivity Among Hospital Pharmacists. <i>Journal of Pharmacy Practice</i> , 2017, 30, 336-341.	1.0	5
34	Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1304-1315.	3.4	26
35	International HTA Experience With Targeted Therapy Approvals For Lung Cancer. <i>Value in Health</i> , 2017, 20, A457-A458.	0.3	1
36	Setting Medical Research Future Fund priorities: assessing the value of research. <i>Medical Journal of Australia</i> , 2017, 206, 63-65.	1.7	9

#	ARTICLE	IF	CITATIONS
37	Health Care and Pharmacy Practice in Jordan. Canadian Journal of Hospital Pharmacy, 2017, 70, 150-155.	0.1	103
38	How often should general practitioners provide nutrition care to patients? A forecasting activity to determine the target frequency for chronic-disease management in Australia. Australian Journal of Primary Health, 2016, 22, 383.	0.9	8
39	Value of Information Analysis Informing Adoption and Research Decisions in a Portfolio of Health Care Interventions. MDM Policy and Practice, 2016, 1, 238146831664223.	0.9	14
40	Efficient Value of Information Calculation Using a Nonparametric Regression Approach: An Applied Perspective. Value in Health, 2016, 19, 505-509.	0.3	11
41	Cost-effectiveness Analysis of Nutritional Support for the Prevention of Pressure Ulcers in High-Risk Hospitalized Patients. Advances in Skin and Wound Care, 2016, 29, 261-267.	1.0	11
42	Quetiapine safety in older adults: a systematic literature review. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 7-18.	1.5	42
43	Cost-Effectiveness and Value of Information Analysis of Nutritional Support for Preventing Pressure Ulcers in High-risk Patients: Implement Now, Research Later. Applied Health Economics and Health Policy, 2015, 13, 167-179.	2.1	14
44	Novel technologies can provide effective dressing and securement for peripheral arterial catheters: A pilot randomised controlled trial in the operating theatre and the intensive care unit. Australian Critical Care, 2015, 28, 140-148.	1.3	29
45	Cost-utility analysis of negative pressure wound therapy in high-risk cesarean section wounds. Journal of Surgical Research, 2015, 195, 612-622.	1.6	96
46	Value of information analysis in healthcare: a review of principles and applications. Journal of Medical Economics, 2014, 17, 377-383.	2.1	49
47	Value of Information Analysis in Oncology: The Value of Evidence and Evidence of Value. Journal of Oncology Practice, 2014, 10, e55-e62.	2.5	18
48	Value of information analysis optimizing future trial design from a pilot study on catheter securement devices. Clinical Trials, 2014, 11, 648-656.	1.6	13
49	Cost-Effectiveness and Value of Information Analyses of Nutritional Support in Preventing Pressure Ulcers in High Risk Hospitalised Patients. Value in Health, 2014, 17, A612-A613.	0.3	0
50	GCSF with or without chemotherapy compared to Plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: Collection effectiveness and cost effectiveness analysis. Journal of Oncology Pharmacy Practice, 2014, 20, 130-136.	0.9	4
51	Cost-Effectiveness Analysis of Clinically Indicated Versus Routine Replacement of Peripheral Intravenous Catheters. Applied Health Economics and Health Policy, 2014, 12, 51-58.	2.1	86
52	The epic3 recommendation that clinically indicated replacement of peripheral venous catheters is safe and cost-saving: how much would the NHS save?. Journal of Hospital Infection, 2014, 87, 183-184.	2.9	11
53	Revision and Validation of a Medication Assessment Tool for Chronic Cancer Pain Management. American Journal of Hospice and Palliative Medicine, 2012, 29, 640-646.	1.4	4
54	Development and implementation of a method for characterizing clinical pharmacy interventions and medication use in a cancer center. Journal of Oncology Pharmacy Practice, 2012, 18, 180-185.	0.9	7

#	ARTICLE	IF	CITATIONS
55	The Effectiveness and Cost Effectiveness of Plerixafor + GCSF Versus GCSF ± Chemotherapy as Salvage Mobilization Regimens in Lymphoma and Multiple Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S247.	2.0	0
56	Comparative Cost Utility Analysis of Plerixafor Plus GCSF Versus Cyclophosphamide Plus GCSF as Salvage Mobilization Regimens in Multiple Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S248.	2.0	2
57	Clinical pharmacy services in the outpatient pediatric oncology clinics at a comprehensive cancer center. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 27-31.	2.1	31
58	Glucarpidase for the treatment of life-threatening methotrexate overdose. <i>Drugs of Today</i> , 2012, 48, 705.	1.1	9
59	Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 136-140.	0.9	11
60	Successful stem-cell mobilization and transplantation using plerixafor in a patient with a germ cell tumor. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2010, 3, 203-205.	0.9	10
61	The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting. <i>Journal of Oncology Pharmacy Practice</i> , 2008, 14, 131-138.	0.9	6